Patients With HCV, Chronic Kidney Disease Less Likely to Receive Antivirals
Individuals with CKD and HCV infection achieve high cure rates with newer anti-HCV treatment regiments.
HCV treatment in all patients with HIV/HCV coinfection decreases levels of immune activation markers, proviral HIV DNA load, and microbial translocation markers.
Enhanced prior authorization and management programs are useful for increasing adherence to therapy in chronic hepatitis C.
Access to treatment could be increased with reductions in price of HBV antivirals.